Nuzenio

Based Avere Therapeutics

Based Avere Therapeutics news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 12 latest news signals 7 publisher sources 100/100 entity strength

Latest news

LigaChem Gains Sole Control of B7-H4 Cancer Drug With Distinct Tumor-Killing Mechanism - Tech TimesTech Times · Fri, 07 Aug 2026 18:29:26 GMT LigaChem Biosciences Takes Solo Control of ADC Cancer Drug After NextCure's Strategic Pivot - finance.biggo.comfinance.biggo.com · Fri, 07 Aug 2026 06:05:00 GMT NextCure reports Q2 2026 net loss $14.9M, cash $20.1M as it pursues merger with Avere - TradingViewTradingView · Thu, 06 Aug 2026 20:35:16 GMT NXTC: Merger with Avere and $320M financing announced as net loss narrows on reduced expenses - TradingViewTradingView · Thu, 06 Aug 2026 20:32:02 GMT NXTC: Merger agreement with Avere Therapeutics drives restructuring, cost cuts, and asset divestitures - TradingViewTradingView · Thu, 06 Aug 2026 20:28:58 GMT NextCure (NASDAQ: NXTC) details Avere merger, $320M financing and going concern risk - Stock TitanStock Titan · Thu, 06 Aug 2026 20:26:26 GMT NextCure (Nasdaq: NXTC) details Q2 2026 loss and Avere merger - Stock TitanStock Titan · Thu, 06 Aug 2026 20:17:25 GMT NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 20:13:40 GMT

Timeline

Fri, 07 Aug 2026 18:29:26 GMTLigaChem Gains Sole Control of B7-H4 Cancer Drug With Distinct Tumor-Killing Mechanism - Tech Times

Fri, 07 Aug 2026 06:05:00 GMTLigaChem Biosciences Takes Solo Control of ADC Cancer Drug After NextCure's Strategic Pivot - finance.biggo.com

Thu, 06 Aug 2026 20:35:16 GMTNextCure reports Q2 2026 net loss $14.9M, cash $20.1M as it pursues merger with Avere - TradingView

Thu, 06 Aug 2026 20:32:02 GMTNXTC: Merger with Avere and $320M financing announced as net loss narrows on reduced expenses - TradingView

Thu, 06 Aug 2026 20:28:58 GMTNXTC: Merger agreement with Avere Therapeutics drives restructuring, cost cuts, and asset divestitures - TradingView

Thu, 06 Aug 2026 20:26:26 GMTNextCure (NASDAQ: NXTC) details Avere merger, $320M financing and going concern risk - Stock Titan

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

Avere9 live mentions NXTC8 live mentions NextCure6 live mentions Merger4 live mentions Avere Therapeutics3 live mentions Stock Titan NextCure3 live mentions Stock Titan Stock3 live mentions Titan3 live mentions Cancer Drug With2 live mentions Distinct Tumor2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Based Avere Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

7 distinct publisher/source names are currently connected to this entity page.